| Nome |
# |
|
Clinical activity after fingolimod cessation: Disease reactivation or rebound?, file e268c4c9-f156-a6b7-e053-3a05fe0adea1
|
338
|
|
Estimates of age-dependent cutoffs for pathological brain volume loss using SIENA/FSL—a longitudinal brain volumetry study in healthy adults, file e268c4c9-f15b-a6b7-e053-3a05fe0adea1
|
300
|
|
Expanded disability status scale progression assessment heterogeneity in multiple sclerosis according to geographical areas, file e268c4c9-adb8-a6b7-e053-3a05fe0adea1
|
250
|
|
Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE), file e268c4ca-d3d1-a6b7-e053-3a05fe0adea1
|
205
|
|
Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study, file e268c4c9-bb8a-a6b7-e053-3a05fe0adea1
|
111
|
|
Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data, file e268c4c9-bb88-a6b7-e053-3a05fe0adea1
|
109
|
|
Learning ability correlates with brain atrophy and disability progression in RRMS, file e268c4c9-f504-a6b7-e053-3a05fe0adea1
|
109
|
|
Gray Matter Correlates of Cognitive Performance Differ between Relapsing-Remitting and Primary-Progressive Multiple Sclerosis, file e268c4ca-09ad-a6b7-e053-3a05fe0adea1
|
109
|
|
Steroid treatment of acute graft-versus-host disease grade I: A randomized trial, file e268c4cb-47f9-a6b7-e053-3a05fe0adea1
|
109
|
|
Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge, file e268c4cc-0e81-a6b7-e053-3a05fe0adea1
|
109
|
|
Optimizing therapy early in multiple sclerosis: An evidence-based view, file e268c4c9-edde-a6b7-e053-3a05fe0adea1
|
103
|
|
Quantitative assessment of finger motor performance: Normative data, file e268c4cb-60f8-a6b7-e053-3a05fe0adea1
|
103
|
|
Cognitive clinico-radiological paradox in early stages of multiple sclerosis, file e268c4c9-bd59-a6b7-e053-3a05fe0adea1
|
99
|
|
Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis - Clinical implementation in the diagnostic process, file e268c4ca-0bce-a6b7-e053-3a05fe0adea1
|
99
|
|
Blood neurofilament light as a potential endpoint in Phase 2 studies in MS, file e268c4ca-c696-a6b7-e053-3a05fe0adea1
|
99
|
|
Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test, file e268c4ca-07de-a6b7-e053-3a05fe0adea1
|
97
|
|
Trans-synaptic degeneration in the optic pathway. A study in clinically isolated syndrome and early relapsing-remitting multiple sclerosis with or without optic neuritis, file e268c4c9-db14-a6b7-e053-3a05fe0adea1
|
96
|
|
Cerebellar volume as imaging outcome in progressive multiple sclerosis, file e268c4c9-db19-a6b7-e053-3a05fe0adea1
|
96
|
|
Defining responders to therapies by a statistical modeling approach applied to randomized clinical trial data, file e268c4cb-032d-a6b7-e053-3a05fe0adea1
|
96
|
|
Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy, file e268c4ca-135e-a6b7-e053-3a05fe0adea1
|
92
|
|
Predictors of hospital-based multidisciplinary rehabilitation effects in persons with multiple sclerosis: a large-scale, single-centre study, file e268c4c9-f398-a6b7-e053-3a05fe0adea1
|
91
|
|
Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis - Establishing disease prognosis and monitoring patients, file e268c4c9-f19d-a6b7-e053-3a05fe0adea1
|
86
|
|
Predicting long-term disability outcomes in patients with MS treated with teriflunomide in TEMSO, file e268c4c9-db05-a6b7-e053-3a05fe0adea1
|
81
|
|
Intra-arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy, file e268c4ca-09af-a6b7-e053-3a05fe0adea1
|
81
|
|
Different MRI patterns in MS worsening after stopping fingolimod, file e268c4c9-f569-a6b7-e053-3a05fe0adea1
|
76
|
|
MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis, file e268c4c9-bd55-a6b7-e053-3a05fe0adea1
|
75
|
|
Effect of fingolimod on diffuse brain tissue damage in relapsing-remitting multiple sclerosis patients, file e268c4c9-fde3-a6b7-e053-3a05fe0adea1
|
75
|
|
Patient outcomes influenced by reduced lymphocyte counts after dimethyl fumarate initiation, file e268c4c9-fdfd-a6b7-e053-3a05fe0adea1
|
75
|
|
An “all-wheel drive” proposal to accelerate clinical research in common and rare neurological diseases, file e268c4cb-a7c2-a6b7-e053-3a05fe0adea1
|
75
|
|
MRI FLAIR lesion segmentation in multiple sclerosis: Does automated segmentation hold up with manual annotation?, file e268c4c9-db0f-a6b7-e053-3a05fe0adea1
|
73
|
|
Brain health: time matters in multiple sclerosis, file e268c4c9-fc2e-a6b7-e053-3a05fe0adea1
|
68
|
|
A Comprehensive Review on Copemyl(®), file e268c4ca-0537-a6b7-e053-3a05fe0adea1
|
68
|
|
Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG, file e268c4ca-27aa-a6b7-e053-3a05fe0adea1
|
67
|
|
High-throughput screening for modulators of ACVR1 transcription: discovery of potential therapeutics for fibrodysplasia ossificans progressiva., file e268c4cb-24f5-a6b7-e053-3a05fe0adea1
|
49
|
|
COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context, file e268c4ce-86d4-a6b7-e053-3a05fe0adea1
|
38
|
|
Enteric Microbiome Markers as Early Predictors of Clinical Outcome in Allogeneic Hematopoietic Stem Cell Transplant: Results of a Prospective Study in Adult Patients, file e268c4c9-d932-a6b7-e053-3a05fe0adea1
|
36
|
|
Innovative quantitative testing of hand function in Charcot-Marie-Tooth neuropathy, file e268c4c7-2bba-a6b7-e053-3a05fe0adea1
|
18
|
|
Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification., file e268c4c6-232b-a6b7-e053-3a05fe0adea1
|
10
|
|
Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis, file e268c4c9-fde5-a6b7-e053-3a05fe0adea1
|
10
|
|
External validation of unsupervised COVID-19 clinical phenotypes and their prognostic impact, file 8667f211-1d12-4413-996c-d35c93fae18d
|
8
|
|
Assessing upper limb function in Multiple Sclerosis by an engineered glove, file e268c4cc-cc58-a6b7-e053-3a05fe0adea1
|
7
|
|
Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis., file e268c4c6-0ce6-a6b7-e053-3a05fe0adea1
|
6
|
|
Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system, file e268c4c6-1161-a6b7-e053-3a05fe0adea1
|
6
|
|
Carry-over effect on IFN-gamma production induced by allergen-specific immunotherapy, file e268c4c6-f80e-a6b7-e053-3a05fe0adea1
|
6
|
|
null, file e268c4ce-2f4e-a6b7-e053-3a05fe0adea1
|
6
|
|
Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis, file e268c4c7-b9b3-a6b7-e053-3a05fe0adea1
|
4
|
|
Multiple sclerosis in the campania region (South Italy): Algorithm validation and 2015–2017 prevalence, file e268c4cc-8fc1-a6b7-e053-3a05fe0adea1
|
4
|
|
Sacubitril/valsartan in real-life European patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis, file a679572f-1c35-44df-bfb1-e00ed166a844
|
3
|
|
Predicting Long-term Disability in Multiple Sclerosis: A Narrative Review of Current Evidence and Future Directions, file cfe42b6a-f6bd-4865-a2db-4d01347a055d
|
3
|
|
Breast Density Assessment Using a 3T MRI System: Comparison among Different Sequences, file e268c4c6-31e7-a6b7-e053-3a05fe0adea1
|
3
|
|
Relationship between soluble HLA-G and HLA-A,-B,-C serum levels, and interferon-γ production after sublingual immunotherapy in patients with allergic rhinitis, file e268c4c8-5f64-a6b7-e053-3a05fe0adea1
|
3
|
|
Autologous hematopoietic stem cell transplantation in multiple sclerosis: A phase II trial., file e268c4c9-f1a0-a6b7-e053-3a05fe0adea1
|
3
|
|
Assessing Repair in Multiple Sclerosis: Outcomes for Phase II Clinical Trials, file e268c4c9-fb12-a6b7-e053-3a05fe0adea1
|
3
|
|
To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy, file e268c4c9-fded-a6b7-e053-3a05fe0adea1
|
3
|
|
Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses, file e268c4c9-fdfb-a6b7-e053-3a05fe0adea1
|
3
|
|
Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience, file e268c4ca-fba7-a6b7-e053-3a05fe0adea1
|
3
|
|
Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders, file e268c4cb-d4d9-a6b7-e053-3a05fe0adea1
|
3
|
|
An Italian programme for COVID-19 infection in multiple sclerosis, file e268c4cc-913e-a6b7-e053-3a05fe0adea1
|
3
|
|
Tocilizumab and steroid treatment in patients with COVID-19 pneumonia, file e268c4cc-ab5a-a6b7-e053-3a05fe0adea1
|
3
|
|
null, file e268c4cd-4a1f-a6b7-e053-3a05fe0adea1
|
3
|
|
Recurrence and Prognostic Value of Asymptomatic Spinal Cord Lesions in Multiple Sclerosis, file e268c4cd-544b-a6b7-e053-3a05fe0adea1
|
3
|
|
Coronavirus disease 2019 in Latin American patients with multiple sclerosis, file e268c4ce-0547-a6b7-e053-3a05fe0adea1
|
3
|
|
Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry, file 58357946-685c-4492-9960-480d8092e2ae
|
2
|
|
The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: A case-control study, file b4b9ba9d-93f2-4d02-9e42-0998e8353210
|
2
|
|
Reliability of patient-reported toxicities during adjuvant chemotherapy, file b59fc651-8987-4c5f-86b6-28b81da5ea41
|
2
|
|
Quantitative assessment of finger motor impairment in multiple sclerosis., file e268c4c6-bfab-a6b7-e053-3a05fe0adea1
|
2
|
|
Adjunct screening with tomosynthesis or ultrasound in women with mammography-negative dense breasts: Interim report of a prospective comparative trial, file e268c4c6-ee7b-a6b7-e053-3a05fe0adea1
|
2
|
|
Clinical baseline factors predict response to natalizumab: their usefulness in patient selection., file e268c4c7-6d09-a6b7-e053-3a05fe0adea1
|
2
|
|
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study, file e268c4c9-b075-a6b7-e053-3a05fe0adea1
|
2
|
|
Neurofilaments as biomarkers in neurological disorders, file e268c4c9-f15d-a6b7-e053-3a05fe0adea1
|
2
|
|
Increased incidence of axonal Guillain-Barré syndrome in La Spezia area of Italy: A 13-year follow-up study, file e268c4c9-f560-a6b7-e053-3a05fe0adea1
|
2
|
|
Classification criteria for autoinflammatory recurrent fevers, file e268c4c9-f564-a6b7-e053-3a05fe0adea1
|
2
|
|
Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution, file e268c4ca-5e6d-a6b7-e053-3a05fe0adea1
|
2
|
|
Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis, file e268c4ca-703d-a6b7-e053-3a05fe0adea1
|
2
|
|
Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: A systematic review and meta-analysis, file e268c4ca-8a10-a6b7-e053-3a05fe0adea1
|
2
|
|
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?, file e268c4ca-9aa1-a6b7-e053-3a05fe0adea1
|
2
|
|
Single-Port Versus Conventional Laparoscopic Cholecystectomy: Better Cosmesis at the Price of an Increased Incisional Hernia Rate?, file e268c4ca-c698-a6b7-e053-3a05fe0adea1
|
2
|
|
Subclinical motor impairment assessed with an engineered glove correlates with magnetic resonance imaging tissue damage in radiologically isolated syndrome, file e268c4cb-5f8d-a6b7-e053-3a05fe0adea1
|
2
|
|
Measuring disability in multiple sclerosis: Walking plus much more, file e268c4cb-80d0-a6b7-e053-3a05fe0adea1
|
2
|
|
MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice, file e268c4cc-9139-a6b7-e053-3a05fe0adea1
|
2
|
|
Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia, file e268c4cc-9b4d-a6b7-e053-3a05fe0adea1
|
2
|
|
Cancer Mortality in Trials of Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis, file e268c4cd-2419-a6b7-e053-3a05fe0adea1
|
2
|
|
Tailoring B cell depletion therapy in MS according to memory B cell monitoring, file e268c4cd-2cd3-a6b7-e053-3a05fe0adea1
|
2
|
|
Evaluation of insulin resistance in a cohort of HIV-infected youth., file e268c4ce-03ca-a6b7-e053-3a05fe0adea1
|
2
|
|
DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France, file e268c4ce-39b8-a6b7-e053-3a05fe0adea1
|
2
|
|
Dimethyl fumarate delays multiple sclerosis in radiologically isolated syndrome, file 786b369c-5f31-4366-9207-c604df375c99
|
1
|
|
Thalamic Damage Predicts the Evolution of Primary-Progressive Multiple Sclerosis at 5 Years, file 78b56e05-3137-49be-85f8-467e5f2a7df9
|
1
|
|
Association of NEDA-4 With No Long-term Disability Progression in Multiple Sclerosis and Comparison With NEDA-3, file 8472721e-7af0-4119-a12d-92fb7c3a029e
|
1
|
|
Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010, file 86c24dcf-50e2-4454-8663-94c40997d96b
|
1
|
|
24 Month Longitudinal Data in Ambulant Boys with Duchenne Muscular Dystrophy, file b3128f3b-8e3b-446b-8abd-a83a578f1526
|
1
|
|
COVID-19 severity among patients with multiple sclerosis treated with cladribine: A systematic review and meta-analysis, file b7c35436-0942-4791-bcc9-90d96396d6bd
|
1
|
|
Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon β-1a, file b8b8efed-8959-44fe-82a0-6c80fdfff5d1
|
1
|
|
Recommendations for observational studies of comorbidity in multiple sclerosis, file b9e178e1-2fff-41bb-acbb-1402e7b0aa5a
|
1
|
|
Fingolimod effect on brain volume loss independently contributes to its effect on disability, file be1f8e91-0ee4-44fa-b56b-a40ce7c11179
|
1
|
|
The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis, file cce95a0e-51ee-45a3-8ad6-6edacda365b0
|
1
|
|
Timed rise from floor as a predictor of disease progression in Duchenne muscular dystrophy: An observational study, file dadbe53b-7059-496e-a990-8cd616910c1c
|
1
|
|
Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach, file e268c4c5-f9fe-a6b7-e053-3a05fe0adea1
|
1
|
|
Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study., file e268c4c6-30fa-a6b7-e053-3a05fe0adea1
|
1
|
|
Impairment in explicit visuomotor sequence learning is related to loss of microstructural integrity of the corpus callosum in multiple sclerosis patients with minimal disability., file e268c4c6-bfa9-a6b7-e053-3a05fe0adea1
|
1
|
|
Diagnostic performance of contrast-enhanced spectral mammography: Systematic review and meta-analysis, file e268c4c6-e41b-a6b7-e053-3a05fe0adea1
|
1
|
| Totale |
4.034 |